Effects of L-Carnitine Supplementation on the Rate of Weight Gain and Biomarkers of Environmental Enteric Dysfunction in Children with Severe Acute Malnutrition: A Double-Blind Randomized Controlled Clinical Trial.
J Nutr
; 154(3): 949-961, 2024 03.
Article
em En
| MEDLINE
| ID: mdl-38331348
ABSTRACT
BACKGROUND:
Severe acute malnutrition (SAM) is a major public health concern among low- and middle-income countries, where the majority of the children encountering this acute form of malnutrition suffer from environmental enteric dysfunction (EED). However, evidence regarding the effects of L-carnitine supplementation on the rate of weight gain and EED biomarkers in malnourished children is limited.OBJECTIVES:
We aimed to investigate the role of L-carnitine supplementation on the rate of weight gain, duration of hospital stays, and EED biomarkers among children with SAM.METHODS:
A prospective, double-blind, placebo-controlled, randomized clinical trial was conducted at the Nutritional Rehabilitation Unit (NRU) of Dhaka Hospital, International Centre for Diarrheal Disease Research, Bangladesh. Children with SAM aged 9-24 mo were randomly assigned to receive commercial L-carnitine syrup (100 mg/kg/d) or placebo for 15 d in addition to standard of care. A total of 98 children with Weight-for-Length-z-score (WLZ) < -3 Standard deviation were enrolled between October 2021 and March 2023. Analyses were conducted on an intention-to-treat basis.RESULTS:
The primary outcome variable, "rate of weight gain," was comparable between L-carnitine and placebo groups (2.09 ± 2.23 compared with 2.07 ± 2.70; P = 0.973), which was consistent even after adjusting for potential covariates (age, sex, Weight-for-Age z-score, asset index, and WASH practices) through linear regression [ß 0.37; 95% confidence interval (CI) -0.63,1.37; P = 0.465]. The average hospital stay was â¼4 d. The results of adjusted median regression showed that following intervention, there was no significant difference in the EED biomarkers among the treatment arms; Myeloperoxidase (ng/mL) [ß -1342.29; 95% CI -2817.35, 132.77; P = 0.074], Neopterin (nmol/L) [ß -153.33; 95% CI -556.58, 249.91; P = 0.452], alpha-1-antitrypsin (mg/mL) [ß 0.05; 95% CI -0.15, 0.25; P = 0.627]. Initial L-carnitine (µmol/L) levels (median, interquartile range) for L-carnitine compared with placebo were 54.84 (36.0, 112.9) and 59.74 (45.7, 96.0), whereas levels after intervention were 102.05 (60.9, 182.1) and 105.02 (73.1, 203.7).CONCLUSIONS:
Although our study findings suggest that L-carnitine bears no additional effect on SAM, we recommend clinical trials with a longer duration of supplementation, possibly with other combinations of interventions, to investigate further into this topic of interest. This trial was registered at clinicaltrials.gov as NCT05083637.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Desnutrição
/
Desnutrição Aguda Grave
Tipo de estudo:
Clinical_trials
Limite:
Child
/
Humans
/
Infant
País/Região como assunto:
Asia
Idioma:
En
Revista:
J Nutr
Ano de publicação:
2024
Tipo de documento:
Article